Olema Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Olema Pharmaceuticals

04/11/2023 03:19

* Olema Pharmaceuticals Inc  OLMA.OQ   OLMA.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Olema
Pharmaceuticals Inc
is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Olema
Pharmaceuticals Inc is $25​, above​ its last closing price
of $16.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.72       -0.73      -0.49     Beat    32.6
 Mar. 31 2023  -0.71       -0.66      -0.70     Missed  -5.5
 Dec. 31 2022  -0.62       -0.65      -0.65     Met     0.3​
 Sep. 30 2022  -0.76       -0.77      -0.57     Beat    25.8
 ​​Jun.        -0.65       -0.64      -0.82     Missed  -27.7
 30 2022                                                
 Mar. 31 2022  -0.61       -0.57      -0.58     Missed  -1.8​
 Dec. 31 2021  -0.50       -0.49      -0.54     Missed  -9.1
 Sep. 30 2021  -0.44       -0.46      -0.45     Beat    1.3
 This summary was machine generated November 4 at 03:19 GMT.  All
figures in US dollars  unless otherwise stated